Class I Indications for Dual Antiplatelet Therapy
Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor has Class I indications in three primary clinical scenarios: acute coronary syndrome (ACS) regardless of management strategy, patients undergoing percutaneous coronary intervention (PCI) with stent implantation, and STEMI patients receiving thrombolysis.
Primary Class I Indications
1. Acute Coronary Syndrome (All Presentations)
In all patients with ACS, DAPT is recommended for at least 12 months unless excessive bleeding risk exists 1, 2, 3.
Specific drug selection (Class I recommendations):
- Ticagrelor (180 mg loading dose, 90 mg twice daily) on top of aspirin is recommended regardless of initial treatment strategy, including patients pre-treated with clopidogrel 1
- Prasugrel (60 mg loading dose, 10 mg daily) on top of aspirin is recommended for P2Y12 inhibitor-naïve patients with NSTE-ACS or STEMI undergoing PCI, unless high risk of life-threatening bleeding exists 1
- Clopidogrel (600 mg loading dose, 75 mg daily) on top of aspirin is recommended when ticagrelor or prasugrel cannot be used (prior intracranial bleeding, need for oral anticoagulation) 1
2. PCI with Coronary Stent Implantation
For stable CAD patients undergoing coronary stent implantation, clopidogrel (600 mg loading dose, 75 mg daily) on top of aspirin is recommended 1.
Duration varies by clinical presentation:
- ACS with stent: 12 months (Class I, Level A) 1
- Stable CAD with stent: minimum duration required, with flexibility based on bleeding risk 4
3. STEMI Patients Receiving Thrombolysis
Clopidogrel (300 mg loading dose in patients <75 years, 75 mg daily) on top of aspirin is recommended in STEMI patients receiving thrombolytic therapy 1.
Critical Implementation Details
Aspirin Dosing
Daily aspirin dose of 75-100 mg is recommended in all patients treated with DAPT 1. Higher doses increase bleeding without improving efficacy.
Bleeding Risk Mitigation (Class I)
- Proton pump inhibitor (PPI) in combination with DAPT is recommended 1
- Radial over femoral access is recommended for coronary angiography and PCI (when performed by expert radial operator) 1
Duration Modifications Based on Bleeding Risk
The 2025 ACC/AHA guidelines 2, 3 provide the most recent Class I recommendation: DAPT with aspirin and oral P2Y12 inhibitor is indicated for at least 12 months as the default strategy in patients with ACS who are not at high bleeding risk.
For high bleeding risk patients, several de-escalation strategies exist:
- Shorter duration (3 months Class IIa, 1 month Class IIb) 4
- Transition to ticagrelor monotherapy ≥1 month after PCI 2, 3
- Aspirin discontinuation 1-4 weeks after PCI with continued P2Y12 inhibitor in patients requiring anticoagulation 2, 3
Common Pitfalls to Avoid
Do NOT administer prasugrel in NSTE-ACS patients when coronary anatomy is not known (Class III recommendation) 1.
Do NOT discontinue DAPT within the first month after stent implantation for elective non-cardiac surgery 1. If surgery is required, continue aspirin if possible and resume P2Y12 inhibitor as soon as safely feasible.
Do NOT use routine platelet function testing to adjust antiplatelet therapy before or after elective stenting 1.
Special Populations
Gender and diabetes: Similar type and duration of DAPT are recommended in male and female patients, as well as in patients with and without diabetes 1.
Prior stent thrombosis: Patients with prior stent thrombosis, especially without correctable causes, should receive prolonged DAPT 1.
Key Nuance
While 12-month DAPT remains the only Class I recommendation, recent evidence 5 questions whether this duration is optimal for all patients, noting that the original CURE trial studied DAPT versus no DAPT (not optimal duration) with average treatment of 9 months. The trend is toward individualized duration based on bleeding risk assessment using tools like PRECISE-DAPT score (≥25 indicates high bleeding risk) 1, though 12 months remains the default Class I recommendation for patients without excessive bleeding risk.